Apollomics (APLM) Stock Price

Apollomics Price

NASDAQ·CLOSED
22.50
​
Market closed

Over the last 5 years Apollomics grew revenue by 35.8% annually, reaching 8.50 M USD. For Apollomics, the net margin of -128.7% is up versus -4,739,849.6% a few years ago. The consensus 12-month price target for Apollomics is 5.87 USD, about 73.9% below where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Apollomics stock price

Access this data via the Eulerpool API

Apollomics business model & stock analysis

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company is headquartered in Foster City, California. The company went IPO on 2021-11-26. The firm is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics has a pipeline of approximately nine drug candidates across multiple programs, six of which are in the clinical-stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is in a Phase II multicohort clinical trial in the United States. The firm is also developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers.

Frequently asked questions about Apollomics

Analysts currently set an average price target of 5.87 USD for the Apollomics stock (median: 5.87 USD), implying -73.9 % versus the latest price. The consensus is based on 8 analyst ratings.

7 analysts currently rate the Apollomics stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Apollomics to generate revenue of 13.26 M USD and earnings per share of -62.50 USD.

Converted at the current exchange rate, the Apollomics share trades at 20.08 EUR (22.50 USD).

The Apollomics share (APLM) is listed on 1 stock exchanges, including: NASDAQ (APLM).

The expected revenue of Apollomics is 13.26 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Apollomics is -134.20 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Apollomics is currently -0.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Apollomics stock.

The price-to-sales ratio (P/S) of Apollomics is currently 3.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Apollomics stock.

The Eulerpool Quality Score for Apollomics is 3/10.

The ISIN of Apollomics is KYG0411D1236. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Apollomics is APLM. The ticker symbol is used to trade Apollomics shares on the stock exchange.

Fair ValueTerminal
20.25 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 26, 2021
ISIN
KYG0411D1236
Cusip
G0411D107
Market capitalization
24.75 M USDMicro Cap
52-Week Range
PEG
-1.05
P/E ratio
P/Ee 2026
-0.36
P/Ee 2027
-0.32
P/Ee 2028
-0.32
P/S
P/Se
3.64
EV/EBIT
—
P/B Ratio
5.09
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
429.82 %
Last updated Oct 10, 2026, 1:45 PM

Apollomics Peer Group

Apollomics Ticker

NASDAQ · APLM

All fundamentals and in-depth analysis of Apollomics

Our stock analysis for Apollomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Apollomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.